Rhumbline Advisers Sells 2,050 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Rhumbline Advisers decreased its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 2.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 96,480 shares of the biopharmaceutical company’s stock after selling 2,050 shares during the period. Rhumbline Advisers owned 0.15% of Celldex Therapeutics worth $3,571,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of CLDX. Headlands Technologies LLC bought a new position in Celldex Therapeutics in the 1st quarter valued at $147,000. CANADA LIFE ASSURANCE Co lifted its position in shares of Celldex Therapeutics by 26.4% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after buying an additional 955 shares during the last quarter. Aigen Investment Management LP bought a new position in shares of Celldex Therapeutics during the 4th quarter worth $251,000. Ameritas Investment Partners Inc. increased its holdings in Celldex Therapeutics by 34.3% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 1,582 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in Celldex Therapeutics in the 1st quarter valued at about $283,000.

Analyst Ratings Changes

A number of equities analysts have weighed in on CLDX shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Monday. Wolfe Research started coverage on shares of Celldex Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Monday, August 12th. Wells Fargo & Company increased their target price on Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Finally, Stifel Nicolaus began coverage on Celldex Therapeutics in a research report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price target for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $63.83.

Celldex Therapeutics Price Performance

NASDAQ CLDX opened at $41.24 on Wednesday. The company’s 50 day simple moving average is $38.35 and its two-hundred day simple moving average is $38.76. Celldex Therapeutics, Inc. has a 1 year low of $22.11 and a 1 year high of $53.18. The stock has a market capitalization of $2.73 billion, a PE ratio of -14.47 and a beta of 1.56.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $1.13 million. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. On average, research analysts anticipate that Celldex Therapeutics, Inc. will post -2.5 EPS for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.